Evidence map›Paper›PMID 36979049›Full record

ArticleBiology2023

Genomic Comparative Analysis of Two Multi-Drug Resistance (MDR)

German Matias Traglia, Fernando Pasteran, Jenny Escalante, Brent Nishimura, Marisel R Tuttobene, Tomás Subils, Maria Rosa Nuñez, María Gabriela Rivollier, Alejandra Corso, Marcelo E Tolmasky and 1 more

Full text read
In one paragraph

Article in Biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Insights intoInternational journal of molecular sciences · 2024
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

German Matias TragliaDepartamento de Desarrollo Biotecnológico, Instituto de Higiene, Facultad de Medicina, Universidad de la Republica, Montevideo 11200, Uruguay.ORCID 0000-0002-4780-5311
Fernando PasteranNational Regional Reference Laboratory for Antimicrobial Resistance (NRL), Servicio Antimicrobianos, Instituto Nacional de Enfermedades Infecciosas, ANLIS Dr. Carlos G. Malbrán, Buenos Aires 1282, Argentina.
Jenny EscalanteCenter for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton, Fullerton, CA 92831, USA.
Brent NishimuraCenter for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton, Fullerton, CA 92831, USA.
Marisel R TuttobeneInstituto de Biología Molecular y Celular de Rosario (IBR, CONICET-UNR), Rosario 2000, Argentina.ORCID 0000-0003-0234-4643
Tomás SubilsInstituto de Procesos Biotecnológicos y Químicos de Rosario (IPROBYQ, CONICET-UNR), Rosario 2000, Argentina.
Maria Rosa NuñezLaboratorio de Microbiología, Hospital Provincial Neuquén Dr. Castro Rendón, Neuquén 8300, Argentina.
María Gabriela RivollierLaboratorio de Microbiología, Hospital Artémides Zatti, Viedma, Rio Negro 8500, Argentina.
Alejandra CorsoNational Regional Reference Laboratory for Antimicrobial Resistance (NRL), Servicio Antimicrobianos, Instituto Nacional de Enfermedades Infecciosas, ANLIS Dr. Carlos G. Malbrán, Buenos Aires 1282, Argentina.
Marcelo E TolmaskyCenter for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton, Fullerton, CA 92831, USA.ORCID 0000-0002-6298-7811
Maria Soledad RamirezCenter for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton, Fullerton, CA 92831, USA.ORCID 0000-0002-9904-7890

Funding

Minority Health and Health Disparities International Research Training ProgramT37MD001368 · NIMHD · CALIFORNIA STATE UNIVERSITY FULLERTON · PI TOLMASKY, MARCELO E · 2005 to 2024
$3.9M
DEALING WITH ANTIBIOTIC RESISTANCE--ANTISENSE TECHNOLOGYR15AI047115 · NIAID · CALIFORNIA STATE UNIVERSITY FULLERTON · PI TOLMASKY, MARCELO E · 2000 to 2022
$1.8M
Identifying host human products responsible for natural transformation of resistance traits in Acinetobacter sppSC3GM125556 · NIGMS · CALIFORNIA STATE UNIVERSITY FULLERTON · PI RAMIREZ, MARIA SOLEDAD · 2018 to 2025
$851k
NIAID NIH HHS R15 AI047115NIGMS NIH HHS SC3 GM125556NIH HHS SC3GM125556, 2R15 AI047115, MHRT 2T37MD001368NIMHD NIH HHS T37 MD001368
6 · The paper itself

Abstract

backgroundAfter the emergence of COVID-19, numerous cases of METHODS AND

results

conclusionsAcquisition or shedding of specific genes could increase the ability of

Indexed as

Acinetobacter baumannii MDRblaNDM-1blaOXA-23COVID-19ST-2

Identifiers

PMID36979049
PMCPMC10045941

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read34
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.